Results 71 to 80 of about 756,852 (217)

Myasthenia Gravis – a new era of treatment options  [PDF]

Myasthenia Gravis is an autoimmune disease of the neuromuscular junction that causes fluctuating fatigable neuromuscular weakness. The spectrum of severity ranges from mild intermittent ptosis to respiratory failure requiring ventilatory support ...
Jennifer Spillane, Narmathey Thambirajah
core   +1 more source

Clinical reasoning in feline non‐ambulatory tetraparesis or tetraplegia: Which combination of clinical information is useful?

Veterinary Record, EarlyView.
Abstract Background Non‐ambulatory tetraparesis or tetraplegia in cats may constitute a diagnostic challenge for general practitioners. Therefore, this study aimed to evaluate if clinical variables from signalment, history, clinical examination and basic ancillary tests are associated with underlying diagnoses in cats with non‐ambulatory tetraparesis ...
Guido Bertoldi, Steven De Decker
wiley   +1 more source

Juvenile myasthenia gravis revealed by respiratory distress: a case report. [PDF]

Batna Journal of Medical Sciences
Juvenile myasthenia gravis is a rare autoimmune disorder of the neuromuscular junction in children, characterized by fluctuating muscle weakness. Although respiratory muscle involvement may occur during the disease course, presentation with acute ...
Zakaria Zoheir ADDOU, Djamila Djahida BATOUCHE, Hana ZERROUT, Amina CHENTOUF   +3 more
doaj   +1 more source

Early onset bilateral juvenile myasthenia gravis masquerading as simple congenital ptosis

, 2017
Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction. Ocular myasthenia gravis presents as ptosis with extraocular motility restriction and is prone to be misdiagnosed as third nerve palsy or congenital or aponeurotic ptosis ...
Alam, MS, Devi Nivean, P, Devi Nivean, Pratheeba, Alam, Md. Shahid   +3 more
core   +1 more source

Tolosa-Hunt syndrome with general myasthenia gravis involvement

Journal of Integrative Neuroscience, 2020
Tolosa-Hunt syndrome is an uncommon disease that exhibits unilateral periorbital pain or headache, accompanied by cranial nerve palsies. Myasthenia gravis is an acquired immune system disease involving the neuromuscular junction. One rare case of Tolosa-Hunt syndrome combined with ocular myasthenia gravis had been reported in the literature, but not ...
Lu, Li, Zhe, Wang, Ming-Ou, Lu
openaire   +3 more sources

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

An evaluation of nipocalimab for the treatment of generalized myasthenia gravis

Expert Opinion on Biological Therapy
Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies targeting the neuromuscular junction. MG, characterized clinically by fluctuating muscle weakness and fatigability, is traditionally treated primarily with corticosteroids and nonspecific immunosuppressive drugs.
Carlo Antozzi, Marie Fitzgibbon
openaire   +2 more sources

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab

, 2016
Introduction: Myasthenia gravis (MG) is an antibody mediated autoimmune neuromuscular disorder characterized by fatigable muscle weakness. A proportion of myasthenia gravis patients are classified as refractory due to non responsiveness to conventional ...
Gummadi, S, Burra, HK, Sodalagunta, MB, Settikere Nataraju, Aravinda, Gummadi, Siddharth, Sudulagunta, SR, Burra, Hemanth Kumar, Sepehrar, M, Sathyanarayana, Deepak, Sudulagunta, Sreenivasa Rao, Bangalore Raja, Shiva Kumar, Sepehrar, Mona, Sodalagunta, Mahesh Babu, Settikere Nataraju, A, Sathyanarayana, D, Bangalore Raja, SK   +15 more
core   +1 more source

Risk factors for generalization of ocular myasthenia gravis

Indian Journal of Ophthalmology
Purpose: To identify potential risk factors for the generalization of ocular myasthenia gravis (OMG). Design: Retrospective cohort study. Methods: This study
Djordjevic, Ivana S, Peric, Stojan, Djordjevic, Stefan A, Lavrnic, Dragana, Marasevic, Kristina, Apostolski, Slobodan, Kosac, Ana, Basta, Ivana   +7 more
openaire   +3 more sources